91精品国产综合久久香蕉的用户体验_震车做爰的视频|HD中文字幕在线播放,久久精品8,天天躁日日躁狠狠躁免费麻豆 ,性一交一性一交肉体

  • 新聞與活動(dòng)

    學(xué)術(shù)成果

Current State-of-the-art In-house and Cloud-Based Applications of Virtual Polymorph Screening of Pharmaceutical Compounds: A Challenging Case of AZD1305

Cryst. Growth Des.?2021, 21, 4, 1972–1983

We demonstrate the successful application of the state-of-the-art AstraZeneca in-house and XtalPi cloud-based virtual polymorph screening workflows in support of stable form selection of crystalline oxabispidine AZD1305, a pharmaceutical compound. Experimental solid form screening had found two polymorphic forms, A and B, with physical stabilities that appeared to be extremely close at ambient temperature. Such observation may make experimental and in silico support of the solid form selection a challenging task. Both computational approaches correctly predicted the ranking and geometry of the stable form B at 0 K. This level of information would be important and sufficient for project support at the late discovery stage. However, metastable form A was predicted by both workflows to be considerably less stable than form B, separated by multiple virtual forms in the lattice energy landscapes. In order to account for the experimentally observed close physical stabilities of forms A and B at ambient temperature, calculation of the free-energy landscape was performed using pseudo-supercritical path method. This allowed the demonstration that, while form B is significantly more stable at 0 K, the two forms display a very close physical stability at ambient temperature. The current work highlights the importance of using advanced virtual polymorph screening to get a more comprehensive insight into identifying the most stable form of a pharmaceutical compound under different experimental conditions.

想繼續(xù)了解更多?

聯(lián)系我們

我們期待您的留言

讓我們知道如何為您提供幫助,我們團(tuán)隊(duì)將24小時(shí)內(nèi)與您聯(lián)系!

姓名
電話
郵箱
國(guó)家/地區(qū)
北京市
天津市
上海市
重慶市
河北省
山西省
遼寧省
吉林省
黑龍江省
江蘇省
浙江省
安徽省
福建省
江西省
山東省
河南省
湖北省
湖南省
廣東省
海南省
四川省
貴州省
云南省
陜西省
甘肅省
青海省
臺(tái)灣省
內(nèi)蒙古自治區(qū)
廣西壯族自治區(qū)
西藏自治區(qū)
寧夏回族自治區(qū)
新疆維吾爾自治區(qū)
香港特別行政區(qū)
澳門特別行政區(qū)
從事行業(yè)
小分子藥物研發(fā)
抗體藥物研發(fā)
CRO/CDMO
投融資機(jī)構(gòu)
高校/研究院所/醫(yī)院
園區(qū)
生物醫(yī)藥產(chǎn)業(yè)
感興趣的業(yè)務(wù)
小分子藥物發(fā)現(xiàn)
抗體藥物發(fā)現(xiàn)
藥物固體形態(tài)研發(fā)
化學(xué)合成服務(wù)(含自動(dòng)化合成)
實(shí)驗(yàn)室自動(dòng)化解決方案
所在公司
是否需要業(yè)務(wù)人員跟進(jìn)?
暫不需要
驗(yàn)證碼

我已閱讀并同意 晶泰科技隱私政策法律聲明